No significant difference in recurrence-free survival (RFS) between TICE and Connaught Bacillus Calmette-Guerin (BCG) strains used in combination with interferon in BCG-naïve and BCG-failure patients with nonmuscle-invasive bladder cancer.
Why this matters
There has been limited investigation on substrain comparative efficacy, though differences in phenotypes and antigenicity have been reported.
BCG naïve patients who received TICE BCG had RFS rates of 80% at 3 mo, 64% at 1 y, and 54% at 2 y.
Connaught BCG patients had RFS rates of 83%, 70%, and 65%, respectively.
Univariable analysis found duration of disease 2 y (P=.04), multifocal tumors (P=.04), tumor size 5 cm vs <0.5 cm (P<0.01), and TICE BCG (P=.05) were associated with increased risk for recurrence.
After controlling for duration of disease, tumor focality, and tumor size, strain was no l...